[1]
|
Nassir, F. (2022) NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules, 12, 824.
https://doi.org/10.3390/biom12060824
|
[2]
|
Riazi, K., Azhari, H., Charette, J.H., et al. (2022) The Prevalence and Incidence of NAFLD Worldwide: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepa-tology, 7, 851-861.
https://doi.org/10.1016/S2468-1253(22)00165-0
|
[3]
|
Yip, T.C., Lee, H.W., Chan, W.K., et al. (2022) Asian Per-spective on NAFLD-Associated HCC. Journal of Hepatology, 76, 726-734. https://doi.org/10.1016/j.jhep.2021.09.024
|
[4]
|
Estes, C., Razavi, H., Loomba, R., et al. (2018) Modeling the Epi-demic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease. Hepatology, 67, 123-133. https://doi.org/10.1002/hep.29466
|
[5]
|
Diaz, L.A., Arrese, M. and Arab, J.P. (2022) Hepatocellular Car-cinoma in Non-Alcoholic Fatty Liver Disease from a Clinical and Public Health Perspective. Hepatobiliary Surgery and Nutrition, 11, 755-758.
https://doi.org/10.21037/hbsn-22-386
|
[6]
|
Juanola, O., Martinez-Lopez, S., Frances, R., et al. (2021) Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. International Jour-nal of Environmental Research and Public Health, 18, 5227. https://doi.org/10.3390/ijerph18105227
|
[7]
|
Wong, W.K. and Chan, W.K. (2021) Nonalcoholic Fatty Liver Disease: A Global Perspective. Clinical Therapeutics, 43, 473-499. https://doi.org/10.1016/j.clinthera.2021.01.007
|
[8]
|
Pingitore, P. and Romeo, S. (2019) The Role of PNPLA3 in Health and Disease. Biochimica et Biophysica Acta— Molecular and Cell Biology of Lipids, 1864, 900-906. https://doi.org/10.1016/j.bbalip.2018.06.018
|
[9]
|
Romeo, S., Kozlitina, J., Xing, C., et al. (2008) Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease. Nat Genet, 40, 1461-1465. https://doi.org/10.1038/ng.257
|
[10]
|
Peng, X.E., Wu, Y.L., Lin, S.W., et al. (2012) Genetic Variants in PNPLA3 and Risk of Non-Alcoholic Fatty Liver Disease in a Han Chinese Population. PLOS ONE, 7, e50256. https://doi.org/10.1371/journal.pone.0050256
|
[11]
|
Boonvisut, S., Yoshida, K., Nakayama, K., et al. (2017) Identi-fication of Deleterious Rare Variants in MTTP, PNPLA3, and TM6SF2 in Japanese Males and Association Studies with NAFLD. Lipids in Health and Disease, 16, 183.
https://doi.org/10.1186/s12944-017-0570-y
|
[12]
|
Namjou, B., Lingren, T., Huang, Y., et al. (2019) GWAS and En-richment Analyses of Non-Alcoholic Fatty Liver Disease Identify New Trait-Associated Genes and Pathways across eMERGE Network. BMC Medicine, 17, 135.
https://doi.org/10.1186/s12916-019-1364-z
|
[13]
|
Dwi Astarini, F., Ratnasari, N. and Wasityastuti, W. (2022) Up-date on Non-Alcoholic Fatty Liver Disease-Associated Single Nucleotide Polymorphisms and Their Involvement in Liver Steatosis, Inflammation, and Fibrosis: A Narrative Review. Iranian Biomedical Journal, 26, 252-268. https://doi.org/10.52547/ibj.3647
|
[14]
|
Gong, D., Li, S., Yu, Z., et al. (2022) Contribution of PNPLA3 Gene Pol-ymorphisms to Hepatocellular Carcinoma Susceptibility in the Chinese Han Population. BMC Medical Genomics, 15, 248.
https://doi.org/10.1186/s12920-022-01394-7
|
[15]
|
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association (2018) Guidelines of Prevention and Treatment for Nonal-coholic Fatty Liver Disease: A 2018 Update. Chinese Journal of Hepatology, 26, 195-203.
|
[16]
|
Sharma, D. and Mandal, P. (2022) NAFLD: Genetics and Its Clinical Implications. Clinics and Research in Hepatology and Gastroenterology, 46, Article ID: 102003. https://doi.org/10.1016/j.clinre.2022.102003
|
[17]
|
Xiang, H., Wu, Z., Wang, J., et al. (2021) Research Progress, Challenges and Perspectives on PNPLA3 and Its Variants in Liver Diseases. Journal of Cancer, 12, 5929-5937. https://doi.org/10.7150/jca.57951
|
[18]
|
Ericson, E., Bergenholm, L. andreasson, A.C., et al. (2022) He-patic Patatin-Like Phospholipase Domain-Containing 3 Levels Are Increased in I148M Risk Allele Carriers and Correlate with NAFLD in Humans. Hepatology Communications, 6, 2689-2701. https://doi.org/10.1002/hep4.2032
|
[19]
|
He, S., Mcphaul, C., Li, J.Z., et al. (2010) A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis. Journal of Biological Chemistry, 285, 6706-6715.
https://doi.org/10.1074/jbc.M109.064501
|
[20]
|
Shang, L. and Mashek, D.G. (2020) The Underpinnings of PNPLA3-Mediated Fatty Liver Emerge. Hepatology, 71, 375-377. https://doi.org/10.1002/hep.30888
|
[21]
|
Kabbani, M., Michailidis, E., Steensels, S., et al. (2022) Human Hepatocyte PNPLA3-148M Exacerbates Rapid Non- Alcoholic Fatty Liver Disease Development in Chimeric Mice. Cell Reports, 40, Article ID: 111321.
https://doi.org/10.1016/j.celrep.2022.111321
|
[22]
|
Alam, S., Islam, M.S., Islam, S., et al. (2017) Association of Single Nucleotide Polymorphism at PNPLA3 with Fatty Liver, Steatohepatitis, and Cirrhosis of Liver. Indian Journal of Gastroenterology, 36, 366-372.
https://doi.org/10.1007/s12664-017-0784-y
|
[23]
|
Chatterjee, A., Basu, A., Das, K., et al. (2021) Exome-Wide Scan Identifies Significant Association of rs4788084 in IL27 Promoter with Increase in Hepatic Fat Content among Indians. Gene, 775, Article ID: 145431.
https://doi.org/10.1016/j.gene.2021.145431
|
[24]
|
Kallwitz, E.R., Tayo, B.O., Kuniholm, M.H., et al. (2019) Ameri-can Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults. Clinical Gas-troenterology and Hepatology, 17, 2301-2309.
https://doi.org/10.1016/j.cgh.2019.02.007
|
[25]
|
Seko, Y., Yamaguchi, K., Mizuno, N., et al. (2018) Combination of PNPLA3 and TLL1 Polymorphism Can Predict Advanced Fibrosis in Japanese Patients with Nonalcoholic Fatty Liver Disease. Journal of Gastroenterology, 53, 438-448. https://doi.org/10.1007/s00535-017-1372-8
|
[26]
|
Liu, W., An-stee, Q.M., Wang, X., et al. (2016) Transcriptional Regulation of PNPLA3 and Its Impact on Susceptibility to Nonalco-holic Fatty Liver Disease (NAFLD) in Humans. Aging (Albany NY), 9, 26-40.
https://doi.org/10.18632/aging.101067
|
[27]
|
Serper, M., Vujkovic, M., Kaplan, D.E., et al. (2020) Validating a Non-Invasive, ALT-Based Non-Alcoholic Fatty Liver Phenotype in the Million Veteran Program. PLOS ONE, 15, e0237430. https://doi.org/10.1371/journal.pone.0237430
|
[28]
|
陈霞. 低密度脂蛋白与糖尿病的关系[J]. 内科, 2012, 7(3): 304-306.
|
[29]
|
Li, J., Zou, B., Yeo, Y.H., et al. (2019) Prevalence, Incidence, and Outcome of Non-Alcoholic Fatty Liver Disease in Asia, 1999-2019: A Systematic Review and Meta-Analysis. The Lancet Gastro-enterology and Hepatology, 4, 389-398.
https://doi.org/10.1016/S2468-1253(19)30039-1
|
[30]
|
Zou, Y., Zhong, L., Hu, C., et al. (2021) LDL/HDL Choles-terol Ratio Is Associated with New-Onset NAFLD in Chinese Non-Obese People with Normal Lipids: A 5-Year Longi-tudinal Cohort Study. Lipids in Health and Disease, 20, 28. https://doi.org/10.1186/s12944-021-01457-1
|
[31]
|
Austin, M.A., Breslow, J.L., Hennekens, C.H., et al. (1988) Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction. JAMA, 260, 1917-1921. https://doi.org/10.1001/jama.1988.03410130125037
|
[32]
|
Chatrath, H., Vuppalanchi, R. and Chalasani, N. (2012) Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 32, 22-29. https://doi.org/10.1055/s-0032-1306423
|
[33]
|
Speliotes, E.K., Massaro, J.M., Hoffmann, U., et al. (2010) Fatty Liver Is Associated with Dyslipidemia and Dysglycemia Independent of Visceral Fat: The Framingham Heart Study. Hepatology, 51, 1979-1987.
https://doi.org/10.1002/hep.23593
|
[34]
|
Siddiqui, M.S., Fuchs, M., Idowu, M.O., et al. (2015) Severity of Nonal-coholic Fatty Liver Disease and Progression to Cirrhosis Are Associated with Atherogenic Lipoprotein Profile. Clinical Gastroenterology and Hepatology, 13, 1000- 1008.e3. https://doi.org/10.1016/j.cgh.2014.10.008
|
[35]
|
Young Kim, S., Mun, S., Yu, J.H., et al. (2022) Association between Small Dense LDL Levels and Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Medicine (Baltimore), 101, e30527.
https://doi.org/10.1097/MD.0000000000030527
|